secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beam Therapeutics Inc. (BEAM)
CIK:        0001745999
Form:       8-K
Filed at:   2022-11-07T23:59:59+00:00
Accession:  0000950170-22-022313
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beam Therapeutics Q3 net loss $109.6M; BEACON trial enrollment started for BEAM-101
--------------------------------------------------------------------------------

- Net loss $109.6M ($1.56/sh) vs $28.1M ($0.42/sh) in Q3 2021; R&D spend $85.3M.
- Cash, cash equivalents and marketable securities $1.1B as of Sep 30, 2022, up from $965.6M.
- Patient recruitment underway in BEACON trial for BEAM-101; first sickle cell patient enrollment expected by year-end 2022.
- BEAM-302 nominated as development candidate for alpha-1 antitrypsin deficiency; targeting in vivo DNA correction of E342K mutation.
- BEAM-201 IND response submitted to FDA after clinical hold; no BEAM-102 IND filing in 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1745999/000095017022022313/0000950170-22-022313-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1745999/000095017022022313/beam-20221107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-022313

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer